Search clinical trials for: GW597599B

Total 7 results

Accenture

Completed

Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)

Post-Operative Nausea and Vomiting (PONV)

Australia
Pfizer

Completed

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

Pneumonia

Belgium, United States
GlaxoSmithKline

Completed

Vestipitant 28-day Tolerance Study

Sleep Disorders

Germany
GlaxoSmithKline

Completed

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

Postoperative Nausea and Vomiting | Nausea and Vomiting, Postoperative

United States, Australia, Poland, Belgium, Canada, Netherlands, Finland, South Africa, Chile, United Kingdom, Czech Republic, Turkey
GlaxoSmithKline

Completed

A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia

Sleep Initiation and Maintenance Disorders

Germany
GlaxoSmithKline

Completed

A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

Depressive Disorder, Major
Accenture

Completed

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

Postoperative Nausea and Vomiting

United States

3

Subscribe